IMIrina K. Malashenkova

Irina K. Malashenkova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irina K. Malashenkova has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An impact of latent toxoplasmosis reactivation on immune system and clinical dynamics in patients with mild cognitive impairment

    by Irina K. Malashenkova, Sergey A. Krynskiy, Nikita A. Khailov, Andrey Y. Ratushnyy, Daniil P. Ogurtsov, Ksenia A. Chernyakova, Olesya V. Anufrieva, Dmitry B. Goncharov, Evgeniya V. Abbazova, Marina S. Baranets, et al.

    Mild cognitive impairment (MCI) in a number of cases precedes the development of dementia. Neuroinflammation is one of the key factors in neurodegeneration pathogenesis. Chronic infections and parasitic infestations contribute significantly to neuroinflammation. It has been evident about a link between systemic inflammation, disorders of cellular and humoral immunity and MCI progression. In this context, of particular interest is a role for a common intracellular pathogen Toxoplasma gondii may be involved in MCI pathogenesis and clinical dynamics. Currently, the frequency and clinical significance of toxoplasmosis reactivation in MCI remain unknown. Given Toxoplasma gondii-related immunotropic effects, it is also relevant to investigate an association between latent toxoplasmosis reactivation, immune parameters and inflammatory mediators in MCI. The study was aimed at assessing the frequency of chronic toxoplasmosis reactivation and its associations with cell immunity, levels of main cytokines and chemokines along with clinical dynamics in MCI. For this, individuals were divided into the following groups: main group included 130 patients with MCI, and comparison group — 81 patients with subjective cognitive impairment (preMCI). The serum was tested for anti-Toxoplasma gondii IgG, IgM, and IgA antibodies using enzyme-linked immunosorbent assay, the concentration of cytokines and chemokines was determined by multiplex assay. Cell immunity was assessed using flow cytometry. The Kruskal–Wallis test was used to assess the significance of differences, followed by pairwise comparisons with Mann–Whitney test. An increased frequency of latent toxoplasmosis reactivation (positive for anti-Toxoplasma gondii IgA in combination with IgG 50 IU/mL) was observed in MCI. In MCI patients, reactivation of toxoplasmosis was associated with impaired activation of Th1-cell immunity (lower total and subset T-cell counts including CD4+CD57+ T-cells and CD8+CD57+ T-cells), as well as increased levels and activation of NK-cells. Higher anti-Toxoplasma gondii IgG level in patients was associated with elevated neuroinflammatory markers CCL4 and CCL20, and with less favorable one-year-follow-up clinical dynamics. The results suggest that reactivation of latent toxoplasmosis in MCI may be clinically relevant, and it is important to determine not only anti-Toxoplasma gondii IgG and IgM, but also IgA to detect it.

  • Open Access

    Immune factors associated with prominent negative symptoms and disease severity in schizophrenia

    by I. K. Malashenkova, S. A. Krynskiy, D. P. Ogurtsov, N. A. Hailov, A. Yu. Ratushnyy, E. A. Filippova, V. D. Melnikova, M. A. Kaydan, G. P. Kostyuk, N. A. Didkovsky, et al.

    Schizophrenia is a severely disabling and clinically heterogeneous disease that manifests with disorders of thinking, motivation and emotions. Negative symptoms of schizophrenia include decreased expression of emotions, poverty of speech, withdrawal from social contacts, anhedonia. They poorly respond to therapy, and their severity has the most significant impact on the functioning and quality of life of patients. Changes in systemic immunity in schizophrenia with pronounced negative symptoms are poorly studied. We have previously shown the relationship of elevated levels of interleukin-10 (IL-10) with the severity of negative symptoms and with morphometric changes in the brain in schizophrenia. The aim of this study was to investigate the relationship of a number of systemic immunity parameters (regulatory and proinflammatory cytokines and indicators of cell immunity) with the severity of negative symptoms and the disease severity in schizophrenia. The study included 94 patients treated in the Psychiatric Clinical Hospital No. 1 named after N.A. Alekseev, 66 of whom had pronounced negative symptoms. The control group consisted of 24 healthy volunteers. ELISA and multiplex analysis were used to determine cytokine levels, and multicolour flow cytometry was used to determine the parameters of cellular immunity. The level of circulating immune complexes was determined by immune turbodimetric analysis. Differences were considered statistically significant at p 0.05. The results of the study showed that the majority of schizophrenia patients, regardless of the severity of negative symptoms, had an increase in the levels of cytokine IL-8. It was shown that the severity of negative symptoms was associated with increased levels of cytokines IL-10, IL-12p40, IL-17E/IL-25 and IL-34. It was also revealed that patients with pronounced negative symptoms had a higher level of CD3-CD19-B cells compared to the control group, which, taking into account the changes of the cytokine profile, indicate possible activation of the B cell link of humoral immunity. The data obtained in this work indicate that in schizophrenia with pronounced negative symptoms and severe course of the disease, there is activation of immunoregulatory and Th2-mechanisms. The results contribute to the understanding of the role of immunity disorders in the pathogenesis of various clinical forms of schizophrenia.


  • Immunological and neuroanatomic markers of the clinical dynamics of MCI and pre-MCI

    by I.K. Malashenkova, S.A. Krynskiy, D.P. Ogurtsov, N.A. Khailov, E.A. Filippova, S.N. Moskvina, V.L. Ushakov, V.A. Orlov, A.V. Andryushchenko, N.G. Osipova, et al.

    Objective. To study the relationship of the parameters of immunity and systemic inflammation with the structural magnetic resonance imaging (MRI) parameters in patients with mild cognitive impairment (MCI) and pre-MCI undergoing neurocognitive rehabilitation to search for candidate markers of its effectiveness. Material and methods. The main group included 49 patients, aged ≥60 years, with MCI and pre-MCI with memory impairment, who underwent a course of neurorehabilitation for 5 weeks. The control group included 19 volunteers of similar age with a total MoCA score of ≥25, who did not have cognitive impairment and immuno-inflammatory disorders. The parameters of cellular and humoral immunity and markers of inflammation were studied, and structural MRI was performed. Results. The content of activated natural killer cells (NK-cells) was increased in MCI and pre-MCI (0.63±0.12% vs. 0.22±0.07% in the control group, p=2.2·10–7). The level of immunoglobulin G (IgG) <12.5 g/l in patients with MCI and pre-MCI with the Montreal Cognitive Assessment Scale (MoCA) score <22 was associated with a decrease in the volume of the right nucleus accumbens (376±35 mm3 in patients with IgG <12.5 g/l (p=0.0013) and 480±44 mm3 at IgG <12.5 g/l, 480±44 mm3 in the control group), as well as with a decrease of the thickness and volume of a number of other cortical zones. A logistic regression model including the level of immunoglobulin G, NK cells, CD8+ NK cells and right amygdala volume was constructed to predict the number of MoCA scores 6 months after the course of rehabilitation (R2=0.57; p<1·10–5; standard error of estimate: 2.93). Conclusion. As a result of this work, the perspectives of assessing the immunological parameters in combination with socio-demographic data and morphometric changes of the brain as potential prognostic markers of the dynamics of cognitive impairment in patients with MCI and pre-MCI after neurorehabilitation has been shown.


  • Polymorphisms of IL10 Immunoregulatory Gene Impact the Morphometric Changes of the Brain in Schizophrenia

    by Irina K. Malashenkova, Vadim L. Ushakov, Sergey A. Krynskiy, Daniil P. Ogurtsov, Ekaterina I. Chekulaeva, Ekaterina A. Filippova, Vyacheslav A. Orlov, Natalia V. Zakharova, Denis S. Andreyuk, Sergey A. Trushchelev, et al.


  • Open Access

    Associations of IL17A G-197A single nucleotide polymorphism with immunological parameters and structural changes of the brain in schizophrenia

    by I. K. Malashenkova, V. L. Ushakov, S. A. Krynskiy, D. P. Ogurtsov, N. A. Khailov, A. Yu. Ratushnyy, E. A. Filippova, N. V. Zakharova, G. P. Kostyuk, Н. А. Дидковский, et al.

    Schizophrenia is a chronic mental disorder that is caused by a complex palette of genetic, epigenetic and environmental factors. Some of the important components of its pathogenesis are systemic inflammation and the dysfunction of immunity, which lead to neuroinflammation, contributing to development of structural brain changes. Earlier we have shown that increase in interleukin-17A levels is associated with morphometric changes and immune dysregulation in schizophrenia. IL17A G-197A (rs2275913) genetic polymorphism is involved in determining interleukin-17A secretion. The goal of this work was to investigate the associations between rs2275913 polymorphism, immune disorders and structural neurovisualization findings in schizophrenia to provide new insights into the immunopathogenesis of this disease. 60 patients aged 18 to 42 years diagnosed with schizophrenia were enrolled. 85 healthy volunteers were included into the control group. Multiplex assay was used to determine cytokine and chemokine serum levels. Rs2275913 polymorphism was assessed by polymerase chain reaction with electrophoretic detection of amplification products. A number of relationships between rs2275913 polymorphism and the immune parameters in schizophrenia were revealed. Carriers of G allele showed significant increase in IFNY, a key cytokine of Th1-link of adaptive immunity, and IL-8, an inflammatory chemokine. Also, increased levels of CXCL16 were observed in patients carrying the G allele. CXCL16 activates secretion of other proinflammatory chemokines and is involved in activation of Th1 adaptive immunity. Associations of heterozygous GA genotype with reduced cortical thickness in a number of areas of the frontal cortex in schizophrenia were found. Changes in cortical thickness in some of these areas, including middle frontal gyrus and orbitofrontal cortex, can be relevant to the pathogenesis of schizophrenia. The results highlight the importance of immunogenetic factors in the pathogenesis of schizophrenia and indicate that the rs2275913 polymorphism requires further studies as a potential biomarker of immune dysregulation and morphometric brain changes in schizophrenia.


  • Open Access

    Levels of chemokines and other inflammatory mediators in patients with mild cognitive impairment undergoing rehabilitation

    by I. K. Malashenkova, S. A. Krynskiy, D. P. Ogurtsov, N. A. Khailov, В. Д. Мельникова, A. V. Andryushenko, V. B. Savilov, M. V. Kurmyshev, G. P. Kostyuk, Н. А. Дидковский

    Alzheimer's disease is the most common neurodegenerative disease in old age. In some cases, it is preceded by mild cognitive impairment (MCI). One of the important components in the pathogenesis of neurodegeneration is chronic neuroinflammation (inflammatory activation of microglia and astrocytes in the brain). Systemic inflammatory response and immune dysregulation may contribute to neuroinflammation. The purpose of this study was to investigate the level of chemokines and other inflammatory mediators in patients with MCI who underwent medical rehabilitation, and to study its associations with the severity of cognitive impairment. The study group included 48 patients with MCI undergoing rehabilitation. Rehabilitation included cognitive therapy, psychotherapy and tasks for unaided performance. Repeated examination was conducted 6 months after the completion of rehabilitation. The control group included 46 healthy volunteers. Multiplex assay was used to determine serum cytokine and chemokine concentrations. Student's t-test was used to assess the significance of differences. Assessment of cognitive functions was performed using international neuropsychological scales. In patients with MCI, we have found an increase in the levels of several cytokines and chemokines (TNFα, CXCL10/IP10, MDC) that regulate systemic inflammation, cellular and humoral mechanisms of adaptive immunity. After the rehabilitation course their levels returned to normal. It was also found that decrease in CCL7 level in the patients before the rehabilitation course is associated with the severity of cognitive impairment. The findings contribute to understanding the role of chemokines in the pathogenesis of MCI, and indicate that their levels can be potential biomarkers of the severity of cognitive impairment. For translation of the findings into clinical practice, their validation in larger studies is needed, as well as assessing the associations between chemokine levels and the severity of cognitive impairment in MCI over long-term follow-up.


  • Open Access

    Association of IL-17A levels with immuneinflammatory profile and structural MRI data in patients with schizophrenia

    by I. K. Malashenkova, V. L. Ushakov, S. A. Krynskiy, D. P. Ogurtsov, N. A. Khailov, A. Yu. Ratushnyy, E. I. Chekulaeva, N. V. Zakharova, G. P. Kostyuk, Н. А. Дидковский, et al.

    IL-17A is a proinflammatory cytokine involved in pathogenesis of some neuroinflammatory diseases of the brain. However, its role in schizophrenia is poorly understood. Currently, noninvasive neuroimaging techniques are widely used to assess abnormalities in brain morphology and interactions of neuronal networks in schizophrenia. The aim of this work was to study associations between IL-17A level and brain morphometric parameters in schizophrenia, in order to clarify immune factors of pathogenesis and search for biomarkers of unfavorable disease course. 45 patients with schizophrenia and 30 healthy volunteers were included into the study. The levels of cytokines (IL-5, IL-6, IL-8, IL-10, IL-17A) and inflammatory markers were determined by ELISA or multiplex analysis. MRI scans were performed with a Siemens Magnetom Verio 3T MRI scanner. We used Kruskal–Wallis test to assess significant differences in immunological parameters followed by Mann–Whitney paired comparison; Student test to assess the significance of differences in morphometric parameters of the brain; Fisher exact test to assess the differences in discrete variables, with the differences considered statistically significant at p < 0.05. IL-17A levels were found to be increased in schizophrenia. Its elevated content was associated with increased levels of C-reactive protein, IL-5, IL-6, IL-8, IL-10, and the presence of morphometric changes of frontal and temporal cortex in the patients. So far, the relationships between IL-17A levels, immunoinflammatory parameters and structural brain changes have not been studied in schizophrenia. In the present work, we found an association of elevated IL-17A levels with decreased cortical thickness in several brain regions, systemic inflammation and activation of Th2-link of adaptive immunity in the patients with schizophrenia. According to the literature, a number of brain areas, where cortical thickness was associated with IL-17A levels may be relevant to pathogenesis of the disease and, in particular, to the development of negative symptoms, including impoverishment of interests, speech, and emotions. The results are important for understanding the role of immune disorders in pathogenesis of schizophrenia, including structural changes of the brain, and suggest that IL-17A may be a biomarker of these disorders. Confirmation of associations between structural neuroimaging findings, laboratory markers of inflammation and immune disorders may provide the basis for new multidisciplinary approaches to the diagnosis and prognosis of schizophrenia.


  • Associations of Morphometric Changes of the Brain with the Levels of IGF1, a Multifunctional Growth Factor, and with Systemic Immune Parameters Reflect the Disturbances of Neuroimmune Interactions in Patients with Schizophrenia

    by Irina K. Malashenkova, Vadim L. Ushakov, Sergey A. Krynskiy, Daniil P. Ogurtsov, Nikita A. Khailov, Ekaterina I. Chekulaeva, Ekaterina A. Filippova, Vyacheslav A. Orlov, Nikolay A. Didkovsky, Natalia V. Zakharova, et al.

  • Open Access

    Neuro-Immune Aspects of Schizophrenia with Severe Negative Symptoms: New Diagnostic Markers of Disease Phenotype

    by I.K. Malashenkova, V.L. Ushakov, N.V. Zakharova, S.A. Krynskiy, D.P. Ogurtsov, N.A. Hailov, E.I. Chekulaeva, A.Y. Ratushnyy, S.I. Kartashov, G.P. Kostyuk, et al.

    The aim of the study was to analyze the immune-inflammatory profile of patients with paranoid schizophrenia and relate it to the severity of negative symptoms and the MRI data in order to identify biomarkers of schizophrenia severity, search for new approaches to therapy, and control its effectiveness. Materials and Methods. The main group included 51 patients with paranoid schizophrenia, the control group - 30 healthy subjects. Patients underwent MRI scans and immunological studies, which included an assessment of natural and adaptive immunity, the systemic level of key pro-inflammatory and anti-inflammatory cytokines, and other markers of inflammation. Results. Disorders of immunity and immunoinflammatory profile in patients with paranoid schizophrenia with severe negative symptoms were revealed for the first time: in the presence of severe negative symptoms (>15 points according to the NSA-4 scale), the levels of humoral immunity factors, cytokines IL-10 and IL-12p40 and neurotrophin NGF were increased as well as the markers of systemic inflammation. Morphometric changes in the brain, typical for patients with schizophrenia, and also specific for patients with severe negative symptoms, were determined. The data analysis revealed correlations between the immune changes with structural changes in some of the brain areas, including the frontal cortex and hippocampus. Associations were found between the levels of anti-inflammatory IL-10, IL-12p40 cytokines and morphometric parameters of the brain, specific only for schizophrenic patients with severe negative symptoms. Conclusion. The interdisciplinary approach, combining brain morphometry with in-depth immunological and clinical studies, made it possible to determine neurobiological, immune, and neurocognitive markers of paranoid schizophrenia with severe negative symptoms. The results are important for further deciphering the pathogenesis of schizophrenia and its subtypes, as well as for the search for new approaches to the treatment of severe forms of the disease.


  • The Relationship between Inflammation, Cognitive Impairments, and Neuroimaging Data in Schizophrenia

    by V. L. Ushakov, I. K. Malashenkova, G. P. Kostyuk, N. V. Zakharova, S. A. Krynskiy, S. I. Kartashov, D. P. Ogurtsov, L. V. Bravve, M. A. Kaydan, N. A. Hailov, et al.